Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112774 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Amira A El-Gazar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, October 6 University, Giza, Egypt. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Ferroptosis, Inflammasomes, NF-E2-Related Factor 2. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Faculty of Veterinary Medicine, Damanhour University.
Abstract (Originalsprache)
Repetitive traumatic brain injury (RTBI) is acknowledged as a silent overlooked public health crisis, with an incomplete understanding of its pathomechanistic signaling pathways. Mounting evidence suggests the involvement of thrombin and its receptor, the protease-activated receptor (PAR)1, in the development of secondary injury in TBI; however, the consequences of PAR1 modulation and its impact on ferroptosis-redox signaling, and NLRP3 inflammasome activation in RTBI, remain unclear. Further, the utilitarian function of PAR1 as a therapeutic target in RTBI has not been elucidated. To study this crosstalk, RTBI was induced in Wistar rats by daily weight drops on the right frontal region for five days. Three groups were included: normal control, untreated RTBI, and RTBI+SCH79797 (a PAR1 inhibitor administered post-trauma at 25 μg/kg/day). The concomitant treatment of PAR1 antagonism improved altered behavior function, cortical histoarchitecture, and neuronal cell survival. Moreover, the receptor blockade downregulated mRNA expression of PAR1 but upregulatedthat of the neuroprotective receptor PPAR-γ. The anti-inflammatory impact of SCH79797 was signified by the low immune expression/levels of NF-κB p65,TNF-α, IL-1β, and IL-18. Consequently, the PAR1 blocker hindered the formation of inflammasome components NLRP3, ASC, and activated caspase-1. Ultimately, SCH79797 treatment abated ferroptosis-dependent iron redox signaling through the activation of the antioxidant Nrf2/HO-1 axis and its subsequent antioxidant machinery (GPX4, SOD) to limit lipid peroxidation, iron accumulation, and transferrin serum increment. Collectively, SCH79797 offered putative preventive mechanisms against secondary RTBI consequences in rats by impeding ferroptosis and NLRP3 inflammasome through activating the PPAR-γ/Nrf2 antioxidant cue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, October 6 University, Giza, Egypt.
- Department of Pharmacology & Toxicology, Ahram Canadian University, Giza, Egypt.
- Department of Pharmacology & Toxicology, Cairo University, Cairo, Egypt. Electronic address: dalaal.abdallah@pharma.cu.edu.eg.
- Department of Pharmacology & Toxicology, Misr University for Science and Technology, Giza, Egypt.
- Department of Pharmacology, Toxicology & Biochemistry, Future University in Egypt, Cairo, Egypt.
Förderung
- Faculty of Veterinary Medicine, Damanhour University
Zitieren
APA
El-Gazar, A. A., Soubh, A. A., Abdallah, D. M., Ragab, G. M., & El-Abhar, H. S. (2024). Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112774
Vancouver
El-Gazar AA, Soubh AA, Abdallah DM, Ragab GM, El-Abhar HS. Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112774
BibTeX
@article{ElGazar2024,
author = {El-Gazar, Amira A and Soubh, Ayman A and Abdallah, Dalaal M and Ragab, Ghada M and El-Abhar, Hanan S},
title = {Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112774}
}
EUVIMED